---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-005897"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2022-08-18T23:59:59+00:00"
generated_at: "2026-06-23T22:50:30.152924+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health reports positive Phase I MAD safety data for concussion drug PRV-002

## Summary
- PRV-002 was safe and well tolerated in 8 healthy volunteers given five daily doses.
- No severe adverse events; vital signs, EKG, and blood labs normal.
- Pharmacokinetics showed linear dose-concentration relationship and no drug accumulation.
- Safety Review Committee unanimously approved start of MAD Cohort II (higher dose).
- Low blood levels suggest intranasal delivery may target brain directly with fewer side effects.

## SEC filing metadata
- accession: 0001683168-22-005897
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2022-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316822005897/0001683168-22-005897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316822005897/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-005897
- JSON: https://secwatch.observer/filing/0001683168-22-005897.json
- Plain text: https://secwatch.observer/filing/0001683168-22-005897.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.